Bitolterol

Bitolterol

SCHEMBL4372

CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB2

The experimentally established mechanism targets of Bitolterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 4/20 0.49
LMNA P02545 3/20 0.50
HIF1A Q16665 3/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
PMP22 Q01453 1/20 0.48
KDM4E B2RXH2 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2D6 P10635 3/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
KCNH2 Q12809 1/20 0.42
CYP2C19 P33261 1/20 0.42
ADRB3 P13945 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bitolterol SCHEMBL4371 1.00 LMNA (0.50) LMNAHIF1AALDH1A1CYP3A4ADRB2
SCHEMBL11277082 0.96 LMNA (0.47) LMNAHIF1AALDH1A1CYP3A4ADRB2
SCHEMBL11287419 0.96 LMNA (0.47) LMNAHIF1AALDH1A1CYP3A4ADRB2
SCHEMBL11290655 0.96 LMNA (0.47) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL30777231 0.95 LMNA (0.54) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL30929319 0.95 LMNA (0.54) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL29385409 0.95 LMNA (0.54) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL28134 0.95 LMNA (0.54) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL28133 0.95 LMNA (0.54) LMNAHIF1AALDH1A1CYP3A4ADRB2
Bitolterol SCHEMBL11286987 0.94 ADRB2 (0.55) LMNAHIF1AALDH1A1CYP3A4ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3853 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547949-B1 METHOD FOR PREHEATING AN AFTER-TREATMENT DEVICE HORSE POWERTRAIN SOLUTIONS S L U (ES) 2026-04-01 EP claimed
EP-4699655-A2 COMPOUNDS TMEM16A LIMITED (GB) 2026-02-25 EP claimed
US-12377105-B2 Compounds TMEM16A LIMITED (GB) 2025-08-05 US claimed
EP-4547949-A1 METHOD FOR PREHEATING AN AFTER-TREATMENT DEVICE Horse Powertrain Solutions, S.L.U. (ES) 2025-05-07 EP claimed
US-20250134835-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. 2025-05-01 US claimed
CN-111683926-B Compounds of formula (I) 企业治疗学有限公司 2024-11-08 CN claimed
EP-3062572-B1 VIRTUAL ANCHOR POINT-BASED WIRELESS LOCATING METHOD, DEVICE AND TERMINAL ZTE CORP (CN) 2024-10-23 EP claimed
US-12037336-B2 Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) Enterprise Therapeutics Limited (GB) 2024-07-16 US claimed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US claimed
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-25 US claimed
WO-1995005805-A1 PROCESS FOR CONDITIONING SUBSTANCES ASTRA AKTIEBOLAG (SE) 1995-03-02 WO claimed
EP-0602181-A1 MEDICINAL AEROSOL FORMULATIONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-06-22 EP claimed
WO-1993004671-A1 MEDICINAL AEROSOL FORMULATIONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-03-18 WO claimed
EP-0527940-A1 DIRECT SPRAY-DRIED DRUG/LIPID POWDER COMPOSITION LIPOSOME TECHNOLOGY, INC. (US) 1993-02-24 EP claimed
WO-1991016882-A1 DIRECT SPRAY-DRIED DRUG/LIPID POWDER COMPOSITION LIPOSOME TECHNOLOGY, INC. (US) 1991-11-14 WO claimed
EP-0209547-B1 DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS RIKER LABORATORIES, INC. (US) 1990-09-12 EP claimed
US-4895719-A SUSPENSION, ENCAPSULATION, DRUG DELIVERY LIPOSOME TECHNOLOGY, INC. (US) 1990-01-23 US claimed
US-4814161-A GLYCEROL PHOSPHATIDE RIKER LABORATORIES, INC. (US) 1989-03-21 US claimed
EP-0209547-A1 DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS. RIKER LABORATORIES INC (US) 1987-01-28 EP claimed
WO-1986004233-A1 DRUG-CONTAINING CHLOROFLUOROCARBON AEROSOL PROPELLENT FORMULATIONS RIKER LABORATORIES, INC. (US) 1986-07-31 WO claimed